Prostate cancer, with a reported prevalence of 35 per hundred thousand in TÃ¼rkiye, ranks third among the most frequently encountered cancers worldwide.
In incisional needle biopsies, it is a challenge to identify malignant glands that are very few or sometimes mixed within benign changes such as adenosis and atrophy.
AMACR is a marker that is seen to have a higher expression in the malignant lesions of the prostate compared to a normal prostate.
In this study, we aimed to retrospectively report the cases where we used this marker, for which we believe that it strongly supports findings of malignancy in our daily routine, and present our findings along with other findings in the literature.
